Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial.
Wen ZhangChunxia DuYongkun SunLin YangChengxu CuiZhichao JiangChengfeng WangJinwang WangAiping ZhouPublished in: Cancer chemotherapy and pharmacology (2018)
Nab-paclitaxel and S-1 regimen has presented encouraging ORR, OS, and manageable toxicities as first-line therapy for advanced pancreatic cancer.